BLOG: A win-win situation is possible for both a cash-strapped NHS and expensive pharmaceutical companies, argues our chief executive, Angela Culhane, who recently addressed an influential forum of health experts at Westminster. The key is to transform earlier detection and treatment of prostate cancer before more expensive drugs even become necessary.
After months of consultation and negotiation, the proposed changes to the Cancer Drugs Fund come into effect. But do they go far enough for men with prostate cancer?
NHS England today closes its consultation on their proposals for a revised Cancer Drugs Fund. We submitted our joint response with Tackle, having first asked you for your verdict. Here’s what we said and just a few of your views that helped form it.
BLOG: Our Director of Support and Influencing, Heather Blake, explains why NHS England's proposed reforms to the Cancer Drugs Fund put them in a financial standoff with Big Pharma, while men with prostate cancer are caught in the middle.
We want to make sure that our response to proposed changes in cancer drug access under NHS England reflects what you think, so we'd like you to share your views in our short survey.
BLOG: The advanced prostate cancer drug was removed from the Fund but has been added back to it during a NICE reappraisal.
BLOG: What happened to "No decision about me without me", asks CEO Owen Sharp.
Earlier this year, NHS England announced that they would be removing several drugs, including the prostate cancer treatment cabazitaxel, from the Cancer Drugs Fund (CDF). That decision comes into effect today, which means that new patients will no longer be able to access this treatment via the CDF.
BLOG: Real change is needed to provide future cancer patients reliable access to innovative and effective treatments, writes CEO Owen Sharp.
NHS England announce that prostate cancer drug cabazitaxel will no longer be available on the Cancer Drugs Fund – another casualty of a failing system.